Approximately 70-90% of grades II-III gliomas contain a single base substitution in one Isocitrate dehydrogenase 1 (IDH1) allele, usually at codon 132. IDH1 converts isocitrate to a-ketoglutarate (aKG). Mutant IDH1converts aKG to 2-hydroxyglutarate (2HG), which inhibits the activity of some aKG-dependent enzymes. The IDH1 mutation is associated with resistance to the DNA methylating agent temozolomide (TMZ) in vitro. However, the resistance mechanism remains unclear and a means of sensitizing cells harboring the IDH1 mutation to TMZ is lacking. Immortalized human astrocytes expressing a wild type or R132H mutant IDH1 gene (mutIDH1) were treated with TMZ for 18-24 hours. Following treatment, mutIDH1 astrocytes demonstrated 7 fold higher survival rates than control astrocytes as determined by clonogenic survival assays. Astrocytes treated with 2HG did not exhibit TMZ resistance. Up to seven days after TMZ treatment, over 30% of control astrocytes remained arrested in G2. In contrast, G2 arrest was resolved by day 3 in mutIDH1 cells. Western blotting of G2 checkpoint regulators revealed increased Polo-like kinase 1 (PLK1) activation and decreased Chk1activation in TMZ-treated mutIDH1 astrocytes. Treatment with PLK1 inhibitor BI2536 sensitized mutIDH1 astrocytes to TMZ. Survival rates were 59% following TMZ treatment, 75% following BI2536 treatment, and 18% following treatment with both. Alkaline comet assay revealed elevated DNA damage in mutIDH1 astrocytes at days 1, 3, and 7 post-TMZ treatment. We conclude that mutant IDH1 promotes TMZ resistance independent of 2HG and fosters G2 checkpoint bypass without full repair of damaged DNA through dysregulation of the Chk1/Plk1 signaling pathway. PLK1 inhibition sensitizes mutIDH1 astrocytes to TMZ, suggesting PLK1 inhibitors may be therapeutically valuable in the treatment of IDH1 mutant gliomas.
